FARMINGDALE, N.Y., Nov. 11, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery, wound and burn care, and other surgical specialties, successfully introduced the new BoneScalpel® MIS Platform to more than 50 of the world's leading minimally invasive spine surgeons, including various surgeon key opinion leaders ("KOLs") last week at the annual Society for Minimally Invasive Spine Surgery ("SMISS") meeting in Las Vegas, NV.
Advancements in minimally invasive spine surgery are making possible procedures that result in less post operative pain, fewer traditional complications, and shorter hospital stays and advanced products like the BoneScalpel MIS Platform have been noted as "game changers" according to Dr. Juan Uribe, University of South Florida, Tampa, Fl. With substantial interest at the exhibition booth and more than 50 leads, it's apparent that, "Dr. Juan Uribe and the Misonix team have successfully developed a compelling ultrasonic MIS solution," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We look forward to expanding the BoneScalpel's growth into MIS spine procedures as the large numbers of surgeons visiting our booth and increased attendance at the hands-on workshop was encouraging."
Surgeons attending SMISS had the opportunity to participate in hands-on training, which was conducted by Dr. Uribe. Prior to demonstrating the product, Dr. Uribe explained the product and its clinical benefits commenting that, "the new BoneScalpel MIS product enables a better, more controlled minimally invasive spine procedure." At the conclusion of the event, Dr. Uribe also commented that, "the new BoneScalpel MIS product was well received by my surgeon colleagues during the Misonix Ultrasonic BoneScalpel Enabled MIS Workshop during the 2015 SMISS Conference."
Amongst those who attended the event, was SMISS Co-Chairman, Dr. Kornelis Poelstra, MD, PhD, The Spine Institute on the Emerald Coast, Destin-Fort Walton, Florida, who commented that, "the Misonix BoneScalpel is an interesting technology capable of positively impacting minimally invasive spine surgery and, while I've not yet had the opportunity to use it clinically, others have shown encouraging results with it." Mr. McManus concluded by commenting, "We are honored to be working with world-renowned surgeons as we further develop this MIS platform of our BoneScalpel technology. The presentation and demonstrations led by Dr. Uribe during the hands-on workshop highlighted the key benefits of the BoneScalpel MIS Platform. The workshop's attendees walked away with a deeper understanding of the BoneScalpel and its value to their patients."
About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.